Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synbio TechROCO:1295 +0.11%42 ROC (Joel Greenblatt) % is 4.54% as of Mar. 2026, which is 69% below its 10-year median of 14.75. GuruFocus rates ROCO:1295 with a GF Score™ of 42/100. The stock has 9 warning signs investors should review. Among 1,324 Biotechnology companies, Synbio Tech ranks better than 83.46% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Synbio Tech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 4.54%.
The historical rank and industry rank for Synbio Tech's ROC (Joel Greenblatt) % or its related term are showing as below:
ROCO:1295'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 9.19 Med: 14.75 Max: 21.08
Current: 9.19
During the past 6 years, Synbio Tech's highest ROC (Joel Greenblatt) % was 21.08%. The lowest was 9.19%. And the median was 14.75%.
ROCO:1295's ROC (Joel Greenblatt) % is ranked better than 83.46% of 1324
companies
in the Biotechnology industry
Industry Median: -303.225
vs ROCO:1295: 9.19
Synbio Tech's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -8.60% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Synbio Tech ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Synbio Tech's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:1295 vs VRTX, REGN, RVMD: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Synbio Tech's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synbio Tech ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Synbio Tech's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Synbio Tech's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 4.54% mean?
Synbio Tech (ROCO:1295) has a ROC (Joel Greenblatt) % of 4.54% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Synbio Tech and its competitors. This is 69% below median its historical median of 14.75. Over the past decade, Synbio Tech's ROC (Joel Greenblatt) % has ranged from 9.19 to 21.08. According to the industry distribution chart, Synbio Tech ranks #219 out of 1324 companies in the Biotechnology industry, placing it in the top 16.5%.
Is Synbio Tech's ROC (Joel Greenblatt) % too high?
Synbio Tech's current ROC (Joel Greenblatt) % of 4.54% is 69% below median its 10-year median of 14.75. Over the past 10 years, this metric has ranged from a low of 9.19 to a high of 21.08. Based on the distribution chart, Synbio Tech ranks #219 out of 1324 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Synbio Tech has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Synbio Tech's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Synbio Tech ranks #219 out of 1324 companies for ROC (Joel Greenblatt) %. This places Synbio Tech in the top 17% of its industry — outperforming the majority of peers. Historically, Synbio Tech's own ROC (Joel Greenblatt) % has ranged from 9.19 to 21.08 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Synbio Tech and its competitors. Synbio Tech's current ROC (Joel Greenblatt) % is 4.54%, which is 69% below median its own 10-year median of 14.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synbio Tech stock overvalued right now?
Synbio Tech (ROCO:1295) has a current ROC (Joel Greenblatt) % of 4.54%. The current ROC (Joel Greenblatt) % is 4.54%, which is 69% below median its 10-year median of 14.75. Synbio Tech's overall GF Score™ is 42/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Synbio Tech (ROCO:1295), the current ROC (Joel Greenblatt) % is 4.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Synbio Tech Inc focus on functional research and manufacturing of probiotics for human health and economic animals. It has two reportable segments, Taiwan and Mainland China Segment to engage in the production and R&D technologies of the Taiwan Segment, including the production and sales of concentrated fermentation liquid, lactobacillus plantarum solid drinks, and lactobacillus plantarum granules for animal husbandry. It generates majority of revenue from Taiwan segment includes production and sale of lactobacillus plantarum powder, lactobacillus plantarum fermentation derivative products, probiotics dietary supplements, probiotics products for pets and economic animals, and probiotics products. It has presence in Taiwan, China, Southeast Asia, and Others.
42GF Score
Get the complete analysis for ROCO:1295
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1295 has been successfully added to your 
